News briefs

Med J Aust 2019; 211 (7): . || doi: 10.5694/mja2.50358
Published online: 7 October 2019

A vaccine developed by researchers at the Griffith University Institute for Glycomics could be used to treat and prevent toxic shock caused by invasive streptococcal disease, which kills more than 160 000 people every year. Group A Streptococci bacteria cause common, non‐life‐threatening illnesses such as impetigo (school sores) and tonsillitis, which are easily spread by coughing, sneezing, and sharing food and drinks. In about one in 100 cases, however, the organism enters the body, causing invasive streptococcal disease; which is potentially life‐threatening; mortality can exceed 25% in even the best equipped medical facilities. When invasive streptococcal disease occurs, some bacterial strains produce more toxins than others, causing streptococcal toxic shock syndrome (STSS). The international research team, which includes scientists from Melbourne and Edmonton, Canada, used a transgenic mouse model to develop the first candidate STSS vaccine, a conserved M protein peptide (“J8”). Vaccination with J8 reduced the bacterial burden in the spleen and blood of infected animals by 3–6 orders of magnitude. Administering antibody to J8 also cleared the infection in treated transgenic mice and reduced the mitogenic and inflammatory activity of the M protein, effects enhanced by adding antibody to the streptococcal pyrogenic exotoxin. The next step will be to produce monoclonal antibodies suitable for trials in humans. The research was published in Science Advances.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.